Literature DB >> 12541063

Regulation of tumor necrosis factor alpha and its specific receptors during Toxoplasma gondii infection in human monocytic cells.

A Belloni1, I Villena, J E Gomez, H Pelloux, A Bonhomme, M Guenounou, J M Pinon, D Aubert.   

Abstract

The coccidian Toxoplasma gondiiis an obligate intracellular parasite which can infect all cell types. Among the cytokines elicited by the immune response to Toxoplasma, tumor necrosis factor alpha (TNF-alpha) acts synergistically with gamma interferon (IFN-gamma) and plays a major role in host cell resistance. We have previously reported that TNF-alpha production induced by IFN-gamma/LPS decreases after T. gondii infection of human myelomonocytic THP-1 cells. Here, we investigated the regulation of TNF-alpha and its specific receptors during T. gondii infection of THP-1 cells. We found that TNF-alpha production was regulated at a post-transcriptional level and that TNF receptor expression was regulated at a pretranscriptional level. The TNF receptor I shedding and the fall in TNF-alpha levels observed after T. gondii infection would thus be induced by a parasite component with serine protease activity. These findings indicate that T. gondii participates not only in controlling the cytotoxic effects of TNF-alpha during the infection process, but also in signal transduction mediated mainly by TNF receptor I.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12541063     DOI: 10.1007/s00436-002-0735-z

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  2 in total

1.  Suppressed production of pro-inflammatory cytokines by LPS-activated macrophages after treatment with Toxoplasma gondii lysate.

Authors:  Eun-Jung Lee; Yoo-Mi Heo; Jong-Hak Choi; Hyun-Ouk Song; Jae-Sook Ryu; Myoung-Hee Ahn
Journal:  Korean J Parasitol       Date:  2008-09       Impact factor: 1.341

2.  In vitro anti-Toxoplasma gondii activity of root extract/fractions of Eurycoma longifolia Jack.

Authors:  Nowroji Kavitha; Rahmah Noordin; Kit-Lam Chan; Sreenivasan Sasidharan
Journal:  BMC Complement Altern Med       Date:  2012-07-10       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.